Ezabenlimab
- Generic Name
- Ezabenlimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2249882-54-8
- Unique Ingredient Identifier
- 5V1UI86573
- Associated Conditions
- -
- Associated Therapies
- -
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 67
- Registration Number
- NCT04752215
- Locations
- 🇺🇸
Florida Cancer Specialists-Sarasota-61670, Sarasota, Florida, United States
🇺🇸Tennessee Oncology, PLLC-Nashville-52568, Nashville, Tennessee, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
- Conditions
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 120
- Registration Number
- NCT03964233
- Locations
- 🇺🇸
NEXT Oncology-Irving-69444, Irving, Texas, United States
🇺🇸NEXT Oncology-San Antonio-65273, San Antonio, Texas, United States
🇪🇸Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 252
- Registration Number
- NCT03468426
- Locations
- 🇫🇷
HOP Timone, Marseille, France
🇫🇷INS Curie, Paris, France
🇦🇺Royal North Shore Hospital-St Leonards-20807, St Leonards, New South Wales, Australia
Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT03383978
- Locations
- 🇩🇪
Johann W. Goethe University Hospital, Department of Neurosurgery, Frankfurt, Germany
🇩🇪Johann W. Goethe University Hospital, Senckenberg Institute of Neurooncology, Frankfurt, Germany
🇩🇪Neurochirurgische Klinik, Universitätsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.